MYOVANT SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Myovant Sciences - MYOV

Reading Time:
< 1
 minutes
Posted: October 26, 2022
A J
Share this article
In this Article

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Myovant Sciences (NYSE: MYOV) to Sumitomo Pharma Co., Ltd. Under the terms of the proposed transaction, shareholders of Myovant will receive only $27.00 in cash for each share of Myovant that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nyse-myov/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

Contacts

Lewis S. Kahn

lewis.kahn@ksfcounsel.com
855-768-1857

Follow CEO Today

Just for you
enus $1x3monthspromo static banner 728x90 c1 v1 (1)
Partner Banner
Free CEO Today Newsletter
Subscribe to CEO Today for the latest news every week.

About CEO Today

CEO Today Online and CEO Today magazine are dedicated to providing CEOs and C-level executives with the latest corporate developments, business news and technological innovations.

Follow CEO Today